Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies.

Autores de IIS La Fe

• Víctor García Bustos

  Autor

• Miguel Salavert Lletí

  Autor

• Rosa Blanes Hernández

  Autor

• Marta Dafne Cabañero Navalón

  Autor

• Marino Blanes Juliá

  Autor

Grupos

• Infección Grave

  

  Investigador Principal

  María Ángeles Tormo Mas

Abstract

Little evidence is available regarding the incidence of CMV disease in patients with solid cancers. Latest data show that approximately 50 % of these patients with CMV PCR positivity developed clinically relevant CMV-viremia, and would require specific therapy. In the clinical arena, CMV reactivation is an important differential diagnosis in the infectological work up of these patients, but guidelines of management on this subject are not yet available. CMV reactivation should be considered during differential diagnosis for patients with a severe decline in lymphocyte counts when receiving chemoradiotherapy or immunochemotherapy with lymphocyte-depleting or blocking agents. Monitoring of CMV reactivation followed by the implementation of preemptive strategies or the establishment of early antiviral treatment improves the prognosis and reduces the morbidity and mortality of these patients.

©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Keywords

• Cytomegalovirus; cancer patients; lymphopenia; antiviral preemptive; strategy